Skip to main content

Market Overview

Why Merck Has Had Underwhelming Start To 2020

Why Merck Has Had Underwhelming Start To 2020

After ending 2019 on an upbeat note, shares of pharma giant Merck & Co., Inc. (NYSE: MRK) have faltered in 2020, and an analyst at BofA Securities delved into probable factors that put the brakes on the rally.

The Merck Analyst

Geoff Meacham maintained a Neutral rating and $90 price target for Merck.

The Merck Thesis

Merck shares are off 10% year-to-date compared to a 1% advance by the NYSE Arca Pharmaceutical Index (NYSE: DRG), with the spin-off announced earlier this month likely dragging the stock.

The spin-off, according to Meacham, is a long-term positive, given the anticipated margin improvement beyond 2023. However, investors are concerned near term, especially as Keytruda numbers were uninspiring in the fourth quarter and the slow growth businesses are forecast to see sales declines in 2021.

See Also: Merck To Spin Off Slow-Growing Women's Health, Legacy, Biosimilars Businesses: What You Need To Know

The $6 billion to $6.5 billion revenue gap stemming from the Women's Health/Legacy Brands spin-off will likely result in a 1% year-over-year revenue decline in 2021 and a 2% fall in 2022, as well as EPS declines in 2021.

Meacham sees Keytruda concentration risk ahead of competitor data due in the first half of 2020, as the anti-PD-1 therapy is on track to make up more than 40% of Merck's revenues post-split.

"We still see Merck as having a strong base I/O and vaccine business with what we expect will be continued acceleration from its core Keytruda franchise for years to come," Meacham wrote in the note. BofA remains sidelined due to the unfavorable spin optics and a lack of high-impact events in the next 6-12 months.

MRK Price Action

Merck's stock traded around $82 per share at time of publication.

Latest Ratings for MRK

Apr 2021SVB LeerinkMaintainsOutperform
Nov 2020BernsteinReinstatesOutperform
Oct 2020SVB LeerinkMaintainsOutperform

View More Analyst Ratings for MRK
View the Latest Analyst Ratings


Related Articles (MRK)

View Comments and Join the Discussion!

Posted-In: BofA Securities Geoff MeachamAnalyst Color Reiteration Analyst Ratings Best of Benzinga

Latest Ratings

FIBKStephens & Co.Downgrades
LEAFCanaccord GenuityDowngrades8.5
AGMSidoti & Co.Downgrades115.0
KEXGabelli & Co.Downgrades
OCGNCantor FitzgeraldDowngrades11.0
View the Latest Analytics Ratings
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
Everything you need to know about the latest SPAC news.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at